Sunshine Biopharma (SBFM) Operating Margin (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly Operating Margin came in at 17.41% in Q2 2026, up 442.0% on a YoY basis from 3.21% in Q2 2025, and down 0.91% quarter-over-quarter from 17.25% in Q1 2026.
Powered by 
Analysis
Sunshine Biopharma (SBFM) Operating Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has reported Operating Margin for 10 consecutive years, with 17.41% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Margin rose 442.0% year-over-year to 17.41%; the trailing twelve-month figure through Jun 2026 stood at 16.65% (up 122.0% YoY), and the FY2025 full-year result was 17.15%, down 49.0% from the prior year.
- Operating Margin slipped to 17.41% in Q2 2026 per SBFM's latest filing, from 17.25% in the prior quarter.
- Across five years, Operating Margin topped out at 11.54% in Q3 2025 and bottomed at 1293.58% in Q3 2022.
- Historically, Operating Margin has averaged 200.03% across 5 years, with a median of 18.07% in 2024.
- The widest YoY moves for Operating Margin: up 218701 bps in 2022, down 30847 bps in 2022.
- Over 5 years, Operating Margin stood at 593.01% in 2022, then soared by 97 bps to 15.46% in 2023, then sank by 37 bps to 21.24% in 2024, then climbed by 2 bps to 20.87% in 2025, then gained by 17 bps to 17.41% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 17.41%, 17.25%, and 20.87% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.81 Bn | 39.16 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.90 Bn | 9.73 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.47 Bn | 5.35 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.32 Bn | 479.50 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.12 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 997.70 Mn | 707.58 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 395.89 Mn | 354.64 Mn | 17.15 Mn | 9.72% |
| 10 | Sunshine Biopharma | 1.55 Mn | -12.20 Mn | 2.43 Mn | -17.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.41% |
| Mar 31, 2026 | -17.25% |
| Dec 31, 2025 | -20.87% |
| Sep 30, 2025 | -11.54% |
| Jun 30, 2025 | -21.83% |
| Mar 31, 2025 | -14.56% |
| Dec 31, 2024 | -21.24% |
| Sep 30, 2024 | -13.12% |
| Jun 30, 2024 | -13.63% |
| Mar 31, 2024 | -17.91% |
| Dec 31, 2023 | -15.46% |
| Sep 30, 2023 | -13.08% |
| Jun 30, 2023 | -18.23% |
| Mar 31, 2023 | -37.37% |
| Dec 31, 2022 | -593.01% |
| Sep 30, 2022 | -1,293.58% |
| Jun 30, 2022 | -462.92% |
| Mar 31, 2022 | -997.48% |
| Dec 31, 2021 | -328.52% |
| Sep 30, 2021 | -985.11% |